Disease · MONDO_0005974

strongyloidiasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. strongyloidiasis. Diseases, record MONDO_0005974. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005974

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: strongyloidiasis; Open Targets
Open Targets ID: MONDO_0005974; Open Targets
Other names: Anguilluliasis, Anguillulosis, Infection by Strongyloides (disorder), disseminated strongyloidiasis; Open Targets
Disease Ontology: DOID:10955; Disease Ontology
MeSH: D013322; MeSH
NCI Thesaurus: C128398; NCI Thesaurus
Orphanet: ORPHA:76; Orphanet
Highest stage of its drugs: Approval, for 1 of its 5 drugs, from DailyMed; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IVERMECTIN	CHEMBL6067487		Approval	DailyMed	8	7	7	Drugs and targets
ALBENDAZOLE	CHEMBL1483	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
DIETHYLCARBAMAZINE	CHEMBL684	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MOXIDECTIN	CHEMBL2104415	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03527732	Efficacy and Safety of IVM/ALB Co-administration	Phase 2/3	1,673	2024-03-20	Trichuriasis	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT04848688	Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis	Phase 3	332	2024-01-24	Strongyloides Stercoralis Infection	IVERMECTIN, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT03605758	Treatment of Strongyloides Infection	Phase 3	51	2023-11-30	Strongyloides Stercoralis Infection, Strongyloidiasis	IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT03676140	Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 3	20,000		Trachoma, Yaws, Lymphatic Filariases, Scabies, Strongyloidiasis	ALBENDAZOLE, AZITHROMYCIN, DIETHYLCARBAMAZINE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT07159373	Better Options for Lymphatic Filariasis Treatment	Phase 3	5,100		Lymphatic Filariasis, Scabies, Strongyloidiasis	ALBENDAZOLE, DIETHYLCARBAMAZINE, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT00207753	Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections	Not applicable	550		Ascariasis, Trichuriasis, Hookworm Infection, Strongyloidiasis, Pediculosis	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT01570504	Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis	Phase 3	312		Strongyloidiasis	IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT00765024	Ivermectin Versus Albendazole for Chronic Strongyloidiasis	Phase 3	90		Chronic Strongyloidiasis	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Moxidectin vs Ivermectin: deaths from any cause	0 of 166	0 of 166	332	NCT04848688	Trial comparisons
Moxidectin vs Ivermectin: serious adverse events	0 of 166	0 of 166	332	NCT04848688	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38517907	DERIVED	1	PubMed
37949090	DERIVED	1	PubMed
35217670	DERIVED	1	PubMed
34856181	DERIVED	1	PubMed
34191812	DERIVED	1	PubMed
31558376	DERIVED	1	PubMed
30885157	DERIVED	1	PubMed
21572981	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005974

GET https://conductscience.org/api/diseases/v1/MONDO_0005974/drugs

API reference For AI assistants